Course Outline

Course Information

• The course begins at the time stated below
• The course is broken up into modules outlined below
• There will be breaks between modules

Free Training Session

FREE to Attend | Recording

Sign up

60 mins | Recording

A Guide to Business Development and Partnering Events 

• Overview of major BD partnering events
• How and What to do before an event (and When!)
• Who to contact for a meeting (and How)
• Effective Follow-Up strategies

Session 1 | Day 1

120 mins | 1:00 PM UK

The Planning and Execution of Out-Licensing Processes

• What is a license?
• The Out-licensing Plan & Process
• Licensing Trends and Risk
• The “Licensability” concept
• Assessing potential partners
• Outreach: maximizing partnering conference value
• Outreach: Alternatives to conferences for out-licensing
• Out-licensing; the strategic perspective

Effective Out-Licensing Communications

• Review of the out-licensing campaign process
• Why a single “pitch” deck is insufficient
• The Core Presentations
  • The “Follow Up” presentation
  • The “Meeting” presentation
  • The “Confidential” presentation
• A formula for writing effective outreach messages
• Data room organization and techniques

Session 2 | Day 2

120 mins | 1:00 PM UK

The Planning and Execution of In-Licensing Processes

• Strategic considerations when in-licensing
  • Importance of strategically defined search criteria
  • The Portfolio vs. Franchise Perspective
  • New Market Entry considerations
• Organizational Implications & Challenges
• Sourcing Licensing opportunities
  • Databases
  • Conferences
  • Other techniques

Effective In-Licensing Communications and Considerations

• Presenting your company
• General evaluation frameworks
• Evaluation challenges
• Diagnosis of unsuccessful in-licensing campaigns

Dr Carlos Velez is the Founder and Managing Partner of Lacerta Bio, an international consultancy specializing in both in- and out-licensing of prescription and non-prescription product candidates and commercial products, across multiple therapeutic areas and markets. He also has extensive experience in business development and licensing, such as valuation, portfolio analysis and prioritization, and business planning. He has presented courses in business development and licensing at partnering events, and customized training programs for clients in Europe and Asia.

Carlos is also the co-founder of Connexin Therapeutics, a company currently raising it second round of financing for the development of retinal neuroprotectants. Prior to the formation of Lacerta Bio in 2010, he was the Director of Business Development at Penwest Pharmaceuticals, where he was responsible for the out-licensing of internally-developed 505(b)(2) programs, as well as the scouting and analysis of in-licensing opportunities in neurology. Penwest was acquired by Endo Pharmaceuticals in 2010. He was also the Chief Business Officer of Lantic Therapeutics (UK) until 2012. Other previous employers include Forest Labs, Frankel Group (now Huron Consulting) and Genencor (now Danisco).

Carlos holds a B.S. in Pharmacy from the Albany College of Pharmacy, a Ph.D. in Pharmacy from the University of North Carolina at Chapel Hill, and an MBA in Technology Management from the Rochester Institute of Technology.